Overview
Biotech firm's Q4 revenue missed analyst expectations
Net income for Q4 missed analyst estimates
Company refinanced term loan with Pharmakon Advisors for non-dilutive capital
Outlook
Company expects 2026 JELMYTO sales between $97 mln and $101 mln
Company anticipates submitting NDA for UGN-103 in second half of 2026
UroGen forecasts 2026 operating expenses at $240 mln to $250 mln
Result Drivers
ZUSDURI LAUNCH - ZUSDURI achieved net sales of $15.8 mln in 2025, reflecting initial launch period ahead of permanent J Code
JELMYTO SALES GROWTH - JELMYTO achieved net product sales of $94 mln in 2025, representing a 7% year-over-year growth
UGN-103 TRIAL SUCCESS - UGN-103 demonstrated a 77.8% three-month complete response rate in the UTOPIA trial
Company press release: ID:nGNX2z4KfB
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $37.84 mln | $39.92 mln (8 Analysts) |
Q4 Net Income | Miss | -$26.36 mln | -$25.36 mln (7 Analysts) |
Q4 Operating Income | Miss | -$19.12 mln | -$16.71 mln (8 Analysts) |
Q4 Pretax Profit | Miss | -$26.64 mln | -$25.43 mln (7 Analysts) |
Q4 Operating Expenses | $53.66 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Urogen Pharma Ltd is $34.00, about 56.7% above its February 27 closing price of $21.70
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)